New Needle-Based heart treatment could help children with Drug-Resistant heart disease
NCT ID NCT06540183
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This study tests a new, less invasive procedure called PIMSRA for children with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is too thick and blocks blood flow. The procedure uses a needle guided by ultrasound to deliver radiofrequency energy to the thickened part of the heart wall, aiming to reduce the blockage. Researchers are checking if it is safe and effective for children under 18 who have not improved with medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a minimally invasive procedure called percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) that uses a needle to deliver radiofrequency energy to the thickened heart muscle
- What this could lead to
- If successful, this procedure could offer a less invasive treatment option for children with obstructive hypertrophic cardiomyopathy who do not respond to medication.
- What could go wrong
- This is an early feasibility study with a small number of participants, so results may not apply to all children. Risks include serious complications like heart failure, abnormal heart rhythms, or need for emergency surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY, OBSTRUCTIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xijing Hospital
Xi'an, Shaanxi, 710032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.